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Purpose: The purpose of this study was to validate the celiac disease diagnoses recorded in 
the Danish National Patient Register. To validate the diagnoses, we used information on duo-
denal biopsies from a national register of pathology reports (the Patobank) and information 
on celiac disease-specific antibodies and human leukocyte antigen (HLA) genotypes obtained 
from patient medical records.
Patients and methods: We included all the children who were born from 1995 to 2012 and who 
were registered as having celiac disease in the Danish National Patient Register. We reviewed all 
the pathology reports on duodenal biopsies in the Patobank and the information in the medical 
records on celiac disease-specific antibodies (ie, anti-tissue transglutaminase 2 IgA and IgG, 
endomysial antibodies IgA, and anti-deamidated gliadin peptide IgG) and HLA genotypes.
Results: We identified 2,247 children who were registered in the Danish National Patient 
Register with celiac disease. Duodenal biopsies for 1,555 of the children (69%) were regis-
tered in the Patobank; 1,127 (50%) had a biopsy that was compatible with celiac disease (ie, 
Marsh 2–3). We accessed the medical records of 95% of the children who were registered in 
the  Danish National Patient Register with celiac disease. We found that 1,510 (67%) had one 
or more positive antibody-test results; 1,120 (50%) had anti-tissue transglutaminase 2, IgA 
at tenfold or greater the upper limit of the normal range and/or positive endomysial antibody 
results. The positive predictive value depended on the criteria used for validation and the types 
and numbers of registrations that were included in the analysis and ranged from 62% (95% 
confidence interval: 60%–64%) to 86% (95% confidence interval: 84%–87%).
Conclusion: Our findings indicate that the Danish National Patient Register is a valuable source 
to identify patients who have been diagnosed with celiac disease. However, validation of the 
diagnoses is warranted before data on the patients are used for research purposes.
Keywords: administrative health register, national patient register, pathology register, medical 
record, histology, serology
Introduction
Celiac disease is a chronic immunomediated disorder that is elicited in genetically 
susceptible individuals by gluten and related prolamins. It is characterized by various 
combinations of clinical manifestations, celiac disease-specific antibodies, human 
leukocyte antigens (HLAs) DQ2 or DQ8, and enteropathy.
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Celiac disease-specific antibodies, ie, anti-tissue transglu-
taminase 2 (tTG2) IgA or IgG, endomysial antibody (EMA) 
IgA, and anti-deamidated gliadin peptide (DGP) IgG, are 
reliable diagnostic tools. tTG2 IgA and EMA have sensitivi-
ties and specificities of ≥90%,1 and they have been used in 
clinical practice in Denmark since the late 1990s. The HLA 
genotypes DQ2 or DQ8 are involved in the pathogenesis 
of celiac disease, and carriage of at least one of them is 
required for an individual to develop celiac disease. However, 
30%–40% of the general population has HLA DQ2/DQ8. 
Therefore, testing for HLA DQ2/DQ8 is primarily used to 
exclude a diagnosis of celiac disease.2 Celiac disease-related 
enteropathy is diagnosed by the histological evaluation of 
duodenal biopsies. The Marsh classification system can be 
used to classify the histopathological changes in duodenal 
biopsies, which are characteristic of but not specific to celiac 
disease. Enteropathy exists on a continuum of severity from 
intraepithelial lymphocytosis (Marsh 1), to hypertrophy of 
crypts (Marsh 2), to increasing villous atrophy (Marsh 3) and 
chronic inflammation of the lamina propria.3
The Danish national guidelines for the diagnosis of 
pediatric celiac disease are based on guidelines from the 
European Society for Paediatric Gastroenterology, Hepatol-
ogy, and Nutrition (ESPGHAN). Until 2012, for a diagnosis 
to be made, the guidelines required a duodenal biopsy with 
histological changes that were compatible with celiac dis-
ease (Marsh 2–3).4 New ESPGHAN guidelines, which were 
published in January 2012, allow for diagnoses of children 
with symptoms of celiac disease based on the presence of 
celiac disease-specific antibodies (ie, tTG2 IgA at ten or more 
times the upper limit of normal [ULN] and positive EMA 
results) and the presence of HLA DQ2/DQ8, omitting the 
biopsy.2 These guidelines were implemented in Denmark in 
January 2013.
In Denmark, children are referred to a pediatric hospital 
department in order to obtain diagnoses of and treatment for 
celiac disease. All hospital visits are recorded in the Danish 
National Patient Register, which is a mandatory administra-
tive health register that is considered to be one of the most 
comprehensive patient registers in the world.5 The Danish 
National Patient Register has been used for reimbursing hos-
pitals since 2000.6 Therefore, the completeness of the records 
on celiac disease diagnoses in the register is expected to be 
high. However, the validity of the records is unclear. We pre-
viously demonstrated that from 1995 to 2010, approximately 
two in three children who were registered as having celiac 
disease in the Danish National Patient Register had biopsies 
that were compatible with celiac disease registered in the 
Patobank, a national Danish database of pathology reports.7
Numerous methods have previously been used to identify 
and validate the celiac disease diagnoses in various types 
of registers.8–11 Incidence registers12–15 and reimbursement 
registers16 tend to use strict diagnostic criteria, which means 
that they often have high levels of validity, though their avail-
ability tends to be limited. Pathology reports on biopsies have 
previously been used to confirm registered diagnoses of celiac 
disease,7,10,17 but the implementation of the new diagnostic 
guidelines for celiac disease means that this option is now 
inadequate.
The objective of this study was to validate the records 
of celiac disease in the Danish National Patient Register for 
children and adolescents in Denmark who were born from 
1995 to 2012. We used a combination of pathology reports 
on duodenal biopsies that were registered in the Patobank 
and data on both celiac disease-specific antibodies and HLA 
genotypes that were obtained from patient medical records.
Patients and methods
We included all the children born from January 1, 1995 to 
December 31, 2012 who had been registered as having celiac 
disease in the Danish National Patient Register by May 8, 
2015. We combined this information with the records of 
duodenal biopsies in the Patobank and with data on celiac 
disease-specific antibodies and HLA genotypes that were 
obtained from medical records. To mitigate against missing 
test results in the medical records, we also obtained data 
on celiac disease-specific antibodies and HLA genotypes 
from the laboratory at the Statens Serum Institut (SSI) and 
the GastroLab at Medical Laboratory F, Gentofte Hospital 
in Denmark.
To evaluate the completeness of celiac disease registra-
tions in the Danish National Patient Register, we included 
children who were born from 1995 to 2012, were not regis-
tered as having celiac disease in the Danish National Patient 
Register, and had a duodenal biopsy recorded in the Patobank 
that was compatible with Marsh 1 or Marsh 2–3, and/or a 
record of a positive test result for celiac disease-specific 
antibodies at the SSI or the GastroLab.
A unique ten-digit personal registration number is 
assigned to everyone who is born or lives in Denmark. All 
public records are linked to these numbers, and they enable 
the individual-level linkage of information from various 
registers and medical records.18
The Danish National Patient Register
The Danish National Patient Register includes information 
on the dates of hospital admissions, discharges, and outpa-
tient visits, and the associated hospitals, departments, and 
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 diagnoses. From 1994 onward, the diagnoses recorded in the 
register have been based on the International Classification 
of Diseases (ICD)-10. Each record involves one primary 
diagnosis, and if relevant one or more secondary diagnoses 
or supplementary codes. The diagnoses can be tentative (ICD-
10 Z03*).5,6 We included all children who were born from 
1995 to 2012 and who were registered as having a diagnosis 
of celiac disease (ICD-10 K900).
The Patobank
The Patobank is a national Danish pathology database that 
includes pathology reports containing information on the 
dates of duodenal biopsies, macroscopic and microscopic 
descriptions of the biopsies, the conclusions, and topo-
graphic, morphologic, and diagnostic codes based on the 
Systematized Nomenclature of Medicine (SNOMED; http://
www.patobank.dk). We applied for all the records up to 2015 
for children who were born from 1995 to 2012 and who were 
registered in the Danish National Patient Register as having 
a diagnosis of celiac disease.
Furthermore, to identify the children who were diagnosed 
with celiac disease but not registered in the Danish National 
Patient Register, we applied for all the records that had topo-
graphic, morphologic, and diagnostic codes that were relevant 
to celiac disease (Table S1) for children who were born from 
1995 to 2012, regardless of their registration status in the 
Danish National Patient Register. These data were available 
only for 1995–2012.
All the pathology reports on duodenal biopsies were 
reviewed by one of the authors (SDS), and were classified as 
being compatible with Marsh 2–3 (ie, intraepithelial lympho-
cytosis, hypertrophy of crypts, and increasing villous atro-
phy), Marsh 1 (ie, intraepithelial lymphocytosis), Marsh 0 (ie, 
normal or no changes related to celiac disease), or as being 
unclassifiable.3 In addition, a total of 100 randomly selected 
pathology reports were reviewed by another author (TPH). 
The two reviewers agreed on each of the 100 classifications.
Medical records
In Denmark, data on celiac disease-specific antibodies and 
HLA DQ2/DQ8 are recorded as laboratory-test results in 
patient medical records. To access relevant information for 
register-based research from medical records, permission is 
required from the Danish health authorities and subsequently 
from the hospital departments responsible for the treatment 
of the patients in question.
We aimed to access the medical records of all the children 
who were born from 1995 to 2012 and who were registered in 
the Danish National Patient Register as having celiac  disease. 
For each patient, we assumed that the department that was 
responsible for celiac disease-related treatments was the 
pediatric or internal medicine department that was associated 
with the most recent registration of celiac disease. If all the 
registrations of celiac disease for a patient were associated 
with departments that would not be expected to treat children 
with celiac disease (eg, orthopedic surgery departments), we 
contacted the department that was associated with the most 
recent registration of celiac disease.
After we had been granted permission, the medical 
records were reviewed either electronically, in person at the 
departments, or by requesting that photocopies of the records 
be mailed by the departmental staff. We extracted data on all 
the test results and their ULN associated with tTG2 IgA and 
IgG, EMA, and DGP antibodies, as well as the HLA DQ2/
DQ8 test results. Information on the manufacturers of the 
test kits was not available.
Additional laboratory data
In Denmark, computerization of medical records began 
during the study period 1995–2012. Computerized test 
results are less likely to be missed when reviewing medical 
records. Therefore, we expected that there would be more 
missing test results for records that were registered early in 
the study period. During the study period, tests for celiac 
disease-specific antibodies and HLA genotypes were ana-
lyzed by a small number of laboratories, primarily the SSI 
laboratory and the GastroLab. Therefore, we included all 
the test results from these two laboratories to increase the 
completeness of data. We were able to obtain 2000–2015 
data from the SSI and 1997–2009 data from the GastroLab. 
These data included information about positive test results 
for children who were born from 1995 to 2012 but who 
were not registered as having celiac disease in the Danish 
National Patient Register.
Validity and completeness of celiac 
disease diagnoses in the Danish National 
Patient Register
In accordance with the criteria in Table 1, we validated the 
celiac disease diagnoses recorded in the Danish National 
Patient Register by combining data on biopsy classifications 
and data on celiac disease-specific antibodies and HLA 
genotypes. To estimate the completeness of the registrations 
of celiac disease in the Danish National Patient Register, 
we identified the children who did not have registrations of 
celiac disease in the Danish National Patient Register but 
who were registered in the Patobank with biopsies that were 
compatible with Marsh 1–3 or who had positive test results 
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Table 1 Assessments of celiac disease diagnoses
Assessmenta Biopsy classification Celiac disease-specific 
antibodies
Additional criteria Registration status in the 
Danish National Patient 
Register, n (%)
Registered Not registered
Definite Compatible with Marsh 2–3 Positive 969 (43) 9 (4)
Any classification tTG2 IgA at ≥10× ULN and 
positive EMA
HLA-positive 78 (3) 0
Any classification tTG2 IgA at ≥10× ULN or 
positive EMA
Recorded after 
January 1, 2013
176 (8) 5 (2)
Compatible with Marsh 2–3 Only negative or no records 158 (7) 49 (20)
Compatible with Marsh 1 tTG2 IgA at ≥10× ULN or 
positive EMA
22 (1) 1 (<1)
Probable Unclassifiable or compatible 
with Marsh 0 or no biopsy 
recorded
tTG2 IgA at ≥10× ULN or 
positive EMA
95 (4) 22 (9)
Possible Compatible with Marsh 1 or 
unclassifiable 
Compatible with Marsh 0 or 
no biopsy recorded
Positive 156 (7) 69 (28)
Unclear 
(insufficient data)
Compatible with Marsh 1 or 
unclassifiable or compatible 
with Marsh 0 or no biopsy 
recorded
Unknown Medical records 
not accessed
65 (3) 88 (36)
Unlikely Compatible with Marsh 1 or 
unclassifiable or
compatible with Marsh 0 or 
no biopsy recorded
Only negative or no records Medical records 
accessed
492 (22) 0
Compatible with Marsh 1 or 
unclassifiable or compatible 
with Marsh 0 or no biopsy 
recorded
Any antibody records HLA-negative 36 (2) 1 (<1)
Note: aThe authors’ assessments of the likelihoods of the diagnoses of celiac disease being correct were based on the biopsy classifications, celiac disease-specific 
antibodies, and HLA genotypes.
Abbreviations: ULN, upper limit of normal; EMA, endomysial antibody; HLA, human leukocyte antigen; tTG2, anti-tissue transglutaminase 2.
for celiac disease-specific antibodies according to the data 
from the SSI laboratory or the GastroLab.
Statistical analysis
Positive predictive values (PPVs) were calculated as the 
proportion of children that fulfilled the validation criteria 
devised by the authors (Table 1) out of all the children who 
were registered with celiac disease in the Danish National 
Patient Register. We used the Wilson method to calculate 
95% confidence intervals (CIs) in Stata 14 (StataCorp LP, 
College Station, TX, USA).
Ethics
The study was approved by the Danish Data Protection 
Agency and the Danish Health Authorities, and for cases 
where the medical records were accessed by the departments 
responsible for treatment of the patient at the following hospi-
tals: Viborg Regional Hospital, Silkeborg Regional Hospital, 
Rigshospitalet, Herlev Hospital, Frederiksberg Hospital, 
Gentofte Hospital, Hvidovre Hospital, Nordsjællands Hos-
pital, Holbæk Hospital, Nykøbing F. Hospital, Næstved Hos-
pital, Slagelse Hospital, Zealand University Hospital Køge, 
Zealand University Hospital Roskilde, Odense University 
Hospital, Hospital Little Belt Kolding, Hospital Little Belt 
Vejle, South-West Jutland Hospital, South Jutland Hospital, 
Aarhus University Hospital, Horsens Regional Hospital, 
Randers Regional Hospital, Aalborg University Hospital Aal-
borg, Aalborg University Hospital Hobro, Herning Regional 
Hospital, North Denmark Regional Hospital Hjørring, and 
North Denmark Regional Hospital Thisted. Patient consent 
from the participants and notification of the regional com-
mittees on health-researchs ethics was not required as this 
was a register-based study not including human biological 
material, and the participants were not contacted (Health 
legislation §46.2 and Legislation for Health-Research-Ethics 
and Health Science Research §14.2).
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Results
The Danish National Patient Register
We identified 2,247 children registered with a primary, sec-
ondary, or tentative diagnosis of celiac disease in the Danish 
National Patient Register, which corresponded to a total of 
20,776 hospital visits. The first registration was on February 
8, 1996, and the most recent registration was on May 7, 2015. 
The median number of hospital visits was six (range 1–143). 
Inpatient admissions accounted for 1,459 of the hospital 
visits. With regard to tentative diagnoses, 147 (6.5%) of the 
children had solely tentative diagnoses. With regard to the 
number of registrations of celiac disease, 322 (14.3%) of the 
children had one registration, and 1,778 (79.1%) had two or 
more registrations (Table 2).
The Patobank
We received all registrations of duodenal biopsy procedures 
for 1,555 of the children in the Danish National Patient 
 Register (Table 3). Each registration was unique in terms of 
the patient and date of the procedure, and each registration 
could include more than one duodenal biopsy (taken dur-
ing the same procedure). We identified 1,170 registrations 
(involving 1,127 children) that were compatible with Marsh 
2–3, 126 registrations (involving 101 children) that were 
compatible with Marsh 1, 461 registrations (involving 298 
children) that were compatible with Marsh 0, and 33 regis-
trations (involving 29 children) that were unclassifiable. The 
unclassifiable biopsies were mostly of very poor quality, and 
so they could not be evaluated by a pathologist.
Among the children with Patobank records that included 
celiac disease-related SNOMED codes (Table S1) but who 
were not registered in the Danish National Patient Register, 
we identified 63 registrations (involving 58 children) that 
were compatible with Marsh 2–3 (Table 4), 94 registrations 
(involving 90 children) that were compatible with Marsh 1 
(Table 4), and 628 registrations that were compatible with 
Table 2 Assessment of the likelihood of celiac disease.
Assessment of 
celiac disease 
likelihooda
All registrations 
(n=2,247), n (%)
Excluding tentative 
diagnoses (n=2,100), 
n (%)
Two or more 
registrations 
(n=1,778), n (%)
No registrationsb 
(n=244), n (%)
Total 
(n=2,491), 
n (%)
Definite 1,403 (62) 1,383 (66) 1,309 (74) 64 (26) 1,467 (59)
Probable 95 (4) 91 (4) 84 (5) 22 (9) 117 (5)
Possible 156 (7) 138 (7) 97 (5) 69 (28) 225 (9)
Unclear 65 (3) 57 (3) 33 (2) 88 (36) 153 (6)
Unlikely 528 (24) 431 (21) 255 (14) 1 (<1) 529 (21)
Notes: aSee criteria in Table 1; bnot registered in the Danish National Patient Register (these patients had biopsies that were compatible with celiac disease or positive 
antibody-test results registered with the Statens Serum Institut laboratory or the GastroLab).
Table 3 Registrations in the Patobank and antibody-test results for children registered with celiac disease in the Danish National 
Patient Register
Antibody-test results from medical 
records
Registration in the Patobank Total
Yes Marsh 2–3 Marsh 1 Unclassifiable or Marsh 0 No
Yes 1,484 (+24a) 1,084 (+10a) 92 (+4a) 308 (+10a) 651 (+6a) 2,135 (+30a)
One or more registrations 1,450 1,070 (+10a) 89 (+4a) 291 (+10a) 583 (+6a) 2,033 (+30a)
One or more positive registrations 1,182 963 (+10a) 75 (+10a) 144 (+10a) 319 (+6a) 1,501 (+30a)
Positive EMA or tTG2 IgA at ≥10× ULN 861 744 (+5a) 35 82 253 (+1a) 1,114 (+6a)
No 71 43 9 19 41 112
Total 1,555 1,127 101 327 692 2,247
Note: aMedical records not accessed; antibody-test results were obtained from the Statens Serum Institut laboratory or the GastroLab.
Abbreviations: EMA, endomysial antibody; tTG2, anti-tissue transglutaminase 2; ULN, upper limit of normal.
Table 4 Registrations in the Patobank and antibody-test results for children not registered with celiac disease in the Danish National 
Patient Register
Antibodies from the SSI or the GastroLab Registration in the Patobank Total
Yes Marsh 2–3 Marsh 1 No
Yes 30 18 12 96 126
Positive EMA results or tTG2 IgA at ≥10× ULN 8 7 1 27 35
No 118 40 78 NR 118
Total 148 58 90 96 244
Abbreviations: EMA, endomysial antibody; NR, not relevant; SSI, Statens Serum Institut; tTG2, anti-tissue transglutaminase 2; ULN, upper limit of normal.
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Marsh 0 or that were unclassifiable. Table S2 shows the 
frequencies of selected SNOMED codes and the Marsh 
classifications of the biopsies.
Medical records
We contacted 72 hospital departments to obtain permission 
to access the medical records of the 2,247 children who were 
registered in the Danish National Patient Register. In total, 
we obtained access to medical records for 2,135 (95%) of 
the children (Table S3). Pediatrics (ie, all 18 of the pediatric 
departments in Denmark) accounted for 1,936 of the children 
(median: 100.5, range: 11–276), and 29 departments of inter-
nal medicine accounted for 245 children (median: 6, range: 
1–42). Furthermore, three departments (which accounted 
for four children) were in private hospitals, ten were surgical 
departments (which accounted for 48 children), three were 
emergency departments (which accounted for three children), 
and nine were other types of departments (which accounted 
for eleven children). In the medical records, we identified 
data on 11,204 blood samples that were unique in terms 
of the patient and the date of the blood collection that had 
tested for or IgG, EMA, or DGP antibodies or HLA DQ2/
DQ8 (Tables 3 and 5).
Additional laboratory data
In the data from the SSI laboratory and the GastroLab, we 
found 48 additional records (involving 30 children) of celiac 
disease-specific antibodies (Table 3) for children who were 
registered as having celiac disease in the Danish National 
Patient Register but whose medical records (associated with 
12 departments) were not accessed (see Table S3 for details). 
Furthermore, for children who were not registered as hav-
ing celiac disease in the Danish National Patient Register, 
we found 167 positive test results (involving 126 children), 
including 94 positive results for tTG2 IgA at ten or more 
times the ULN or for EMA (involving 80 children) (Table 4).
Table 5 Assessments of the likelihood of celiac disease for various registrations in the Danish National Patient Register
Characteristics Total  
(n=2,247)
Assessmenta
Definite  
(n=1,403)
Probable  
(n=95)
Possible  
(n=156)
Unclear  
(n=65)
Unlikely  
(n=528)
Age at the end of the study period 
(May 8, 2015), yearsb
13.1 (9.3–16.7) 13.2 (9.7–17.7) 14.7 (10.5–16.9) 11.6 (8–15.9) 15.8 (11.4–18.8) 12.7 (8.9–16.3)
Femalec 1,362 (61) 902 (64) 61 (64) 98 (63) 41 (63) 260 (49)
Danish National Patient Register
Age at first registration, yearsb 4.2 (1.9–7.6) 4 (1.8–7.3) 4.7 (2.9–9.9) 2.6 (1.2–4.7) 2.9 (1.1–6.5) 5.7 (2.6–9.4)
Registrations per childb 6 (2–12) 8 (4–15) 8 (4–13) 3 (1–6) 2 (1–4) 2 (1–3.5)
1 registrationc 417 (19) 87 (6) 10 (11) 50 (32) 30 (46) 240 (45)
2–4 registrationsc 565 (25) 287 (20) 17 (18) 51 (33) 21 (32) 189 (36)
5–9 registrationsc 551 (25) 418 (30) 34 (36) 30 (19) 6 (9) 63 (12)
10–14 registrationsc 307 (14) 258 (18) 13 (14) 15 (16) 4 (6) 17 (3)
≥15 registrationsc 407 (18) 353 (25) 21 (22) 10 (6) 4 (6) 19 (4)
Patobank
Children with biopsy registrationc 1,555 (69) 1,188 (85) 57 (60) 93 (60) 25 (39) 192 (36)
Age at first registration, yearsb 5.1 (2.5–8.1) 5 (2.5–7.7) 6 (4.2–10.6) 3.1 (1.9–5.2) 3.1 (2.1–6.3) 7.1 (4.2–10.4)
Antibody tests
Antibody tests per child (dates)b 4 (2–7) 6 (4–8) 7 (5–9) 3 (2–6) 0 1 (1–3)
Age at first test, yearsb 4.7 (2.3–7.8) 4.5 (2.2–7.3) 5.7 (3.3–9.6) 2.9 (1.6–6) 10.4 (6.8–12.6) 6.2 (3.1–9.5)
Age at first positive test, yearsb 3.6 (1.9–6.7) 3.8 (1.9–6.9) 5.5 (3.2–9) 2.5 (1.3–4.2) – 2.7 (1.4–4.2)
tTG2 IgA tests per childb 7 (4–10) 7 (5–10) 8 (6–11) 5 (3–7) 0 (0–1) 3 (1–5)
Children with tTG2 IgA testsc 2,043 (91) 1,351 (96) 95 (100) 156 (100) 14 (22) 427 (81)
Children with positive tTG2 IgA testsc 1,443 (64) 1,208 (86) 94 (99) 131 (84) 0 10 (2)
Children with tTG2 IgA at ≥10× ULNc 1,011 (45) 938 (67) 73 (77) 0 0 0
Children with EMA testsc 688 (31) 471 (34) 41 (43) 37 (24) 4 (6.2) 135 (26)
Children with positive EMA testsc 429 (19) 392 (28) 37 (39) 0 0 0
Children with tTG2 IgG testsc 478 (21) 304 (22) 25 (26) 35 (22) 1 (2) 113 (21)
Children with positive tTG2 IgG testsc 145 (7) 121 (9) 9 (10) 15 (10) 0 0
Children with DGP testsc 964 (43) 701 (50) 31 (33) 105 (67) 1 (1.5) 126 (24)
Children with positive DGP testsc 447 (20) 360 (26) 19 (20) 63 (40) 0 5 (0.95)
HLA genotype
Children with HLA testsc 420 (19) 255 (18) 21 (22) 52 (33) 3 (4.6) 89 (17)
Children with HLA DQ2/DQ8c 379 (17) 251 (18) 20 (21) 52 (33) 3 (4.6) 53 (10)
Notes: aSee criteria in Table 1; bmedian (interquartile range); cnumber (%).
Abbreviations: ULN, upper limit of normal; EMA, endomysial antibody; DGP, deamidated gliadin peptide; HLA, human leukocyte antigen.
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Validity of celiac disease diagnoses in the 
Danish National Patient Register
Table 2 shows the distribution of celiac disease registra-
tions in the Danish National Patient Register according 
to the criteria in Table 1 for definite, probable, possible, 
unclear, and unlikely diagnoses of celiac disease. Of the 
2,247 children registered as having celiac disease in the 
Danish National Patient Register, 1,403 were considered 
to be correctly  registered with celiac disease (ie, they had 
definite diagnoses). Another 95 children probably had celiac 
disease, based on the fact that they had tTG2 IgA at ten or 
more times the ULN or positive EMA results, but lacked 
evidence of histological changes. In addition, 156 children 
possibly had celiac disease, based on the fact that their test 
results were positive for celiac disease-specific antibodies, 
but they lacked evidence of histological changes. However, 
65 cases were unclear due to insufficient information (ie, 
we could not access the relevant medical records), and 528 
children were unlikely to have been correctly registered in the 
Danish National Patient Register. These results correspond 
to a PPV that ranged from 62.4% (95% CI: 60.4%–64.4%) 
if only the definite diagnoses are taken into account to 76.5% 
(95% CI: 74.7%–78.2%) if the definite, probable, possible, 
and unclear diagnoses are taken into account.
If we exclude the children who had only tentative diag-
noses registered in the Danish National Patient Register, the 
number of children who were unlikely to have been correctly 
registered in the Danish National Patient Register decreases 
to 431. This results in a PPV that ranges from 65.9% (95% 
CI: 63.8%–67.9%) if only the definite diagnoses are taken into 
account to 79.4% (95% CI: 77.7%–81.1%) if the definite, prob-
able, possible, and unclear diagnoses are taken into account.
If we include only children with two or more registrations 
of celiac disease in the Danish National Patient Register, the 
number of children who were unlikely to have been correctly 
registered in the Danish National Patient Register decreases 
to 255. This results in a PPV that ranges from 73.6% (95% 
CI: 71.5%–75.6%) if only the definite diagnoses are taken into 
account to 85.6% (95% CI: 84%–87.2%) if the definite, prob-
able, possible, and unclear diagnoses are taken into account.
As indicated in Figure 1, the PPVs increased over time 
during the study period. The proportion of children who were 
registered with celiac disease in the Danish National Patient 
Register and who also had a duodenal biopsy registered 
in the Patobank dropped from 78% for those registered in 
1996–2012 to 56% for those registered in 2013–2015 (data 
not shown). The proportion of biopsies that were compat-
ible with Marsh 2–3 remained the same over time (73% for 
those registered in 1996–2012 and 70% for those registered 
in 2013–2015; data not shown).
Completeness of celiac disease diagnoses 
in the Danish National Patient Register
We categorized 20 children who were recorded in the Danish 
National Patient Register as having only tentative diagnoses 
of celiac disease as having definite diagnoses of celiac dis-
ease. We identified an additional 64 children who were not 
recorded as having celiac disease in the Danish National 
Patient Register, but who fulfilled the criteria for a definite 
diagnosis of celiac disease. These children were either reg-
istered in the Patobank with a biopsy that was compatible 
with Marsh 2–3 or records from the SSI laboratory or the 
GastroLab showed that they had tTG2 IgA at ten or more 
times the ULN or positive EMA results (Table 2).
Discussion
We carried out a national validation study of celiac disease 
diagnoses that was based on duodenal biopsies, celiac 
disease-specific antibodies, and HLA genotypes. We found 
that the PPV of celiac disease diagnoses depended on the 
criteria used for validation and the types and numbers of 
registrations in the Danish National Patient Register that were 
included in the analysis. The PPV ranged from 62% (95% 
CI: 60%–64%) if only the definite diagnoses were taken into 
account to 86% (95% CI: 84%–87%) if only patients with 
two or more registrations were included and the definite, 
probable, possible, and unclear diagnoses were taken into 
account. To our knowledge, this is the first study to include 
information on biopsies, antibodies, and HLA genotypes to 
validate celiac disease diagnoses in a national patient register. 
Our findings are in-line with results from other validation 
studies of celiac disease diagnoses.
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Figure 1 Assessment of celiac disease by year of first registration in the Danish 
National Patient Register.
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In the Norwegian National Patient Register, 82%–83% of 
the children who were registered from 2008 to 2009 had a sec-
ond diagnosis registered from 2008 to 2011, which increased 
the likelihood of having a correct diagnosis.8 The diagnoses 
of children that participated in the Norwegian Mother and 
Child Cohort Study were validated by collecting data using 
postal questionnaires sent to the families of children with 
two or more registrations of celiac disease in the Norwegian 
National Patient Register (n=468). The response rate was 
63%, and 94% of the responses confirmed the diagnoses 
(83% of cases involved biopsy confirmations).9
In an Italian study in the region of the Friuli-Venezia 
Giulia region, 71% of children with a hospital-discharge 
diagnosis of celiac disease (n=1,227) had a relevant code 
recorded in a pathology register.10
In the UK, a single celiac disease registration per patient 
with the Clinical Practice Research Datalink service had a 
PPV of 81%, which increased to 89% after including only 
patients who had received gluten-free food prescriptions and 
to 100% after including only patients who had two diagnostic 
codes for celiac disease rather than one. However, there was 
a loss of sensitivity when the criteria were more restrictive.11
In Sweden12–14 and Italy,15 celiac disease-specific inci-
dence registers that cover a proportion of the population and 
include information on histology and other diagnostic criteria 
have been established.
A validation study of the biopsies registered in the Swed-
ish database of pathology found that 90% of the biopsies 
were correctly classified as indicating villous atrophy and 
56% correctly classified as indicating small intestinal inflam-
mation. Among the 121 patients registered as having villous 
atrophy, 89% had celiac disease based on a review of their 
medical records.17
A Finnish study validated 10% of the cases of govern-
mental reimbursement for gluten-free food, and found that 
1.17% of the cases did not fulfill the diagnostic criteria, 
despite the fact that this was a prerequisite for receiving the 
reimbursements.
Other studies have used national patient registers19 or 
discharge registers20 without16 carrying out a validation of 
the diagnoses.
Current diagnostic guidelines provide a gold standard for 
diagnosis, but diagnoses rely on the validity and complete-
ness of the data on the items in the guidelines. In everyday 
clinical practice, these data may be of low quality, missing, or 
misinterpreted, which leads to inferior diagnoses (compared 
to gold-standard diagnoses). This study reflects clinical prac-
tice, as it involves data that are inherently somewhat unclear 
and incomplete compared to ideal data.
We accessed medical records for 95% of the children that 
were registered as having celiac disease in the Danish National 
Patient Register. These medical records contained data on 
celiac disease-specific antibody-test results, but some results 
may have been missing. The oldest results are more likely to 
have been missing because they were not computerized. These 
older results can be more important than the more recent 
results, because they represent the tests that were completed 
at the time of each patient’s first diagnosis. We sought to 
diminish the issue of missing data by obtaining information 
from the two primary laboratories that carried out the relevant 
tests during the early study period. In addition, early on in 
the study period, in accordance with the guidelines, all the 
children should have been diagnosed on the basis of a biopsy, 
and thus all the diagnoses should have been included in the 
Patobank. A negligible number of patients refused to have a 
biopsy, as a biopsy was the only recommended confirmatory 
test and having a biopsy was necessary in order for them to 
be financially reimbursed for gluten-free food.
The current diagnostic guidelines are based on tests with 
high sensitivity and specificity, but we do not have informa-
tion on the manufacturers of the test kits used during the study 
period, which would have allowed us to check the sensitivity 
and specificity of the tests. However, although we have no 
information on whether the tests used would have met the 
criteria, we have no reasons to suspect that they would have 
failed to meet the criteria.
For the children who were not registered in the Danish 
National Patient Register, we only have information on anti-
bodies from two laboratories. Therefore, the estimates of the 
completeness of the records in the Danish National Patient 
Register were underestimated and calculations of sensitivity 
and specificity were not possible. However, it was found that 
20 children who had records of only tentative diagnoses in the 
Danish National Patient Register were categorized as having 
a definite diagnosis of celiac disease. The completeness of 
the Danish National Patient Register is an important factor 
for conclusions to be made about the prevalence of diagnosed 
celiac disease in Denmark, but it may be of less importance in 
epidemiological association studies of celiac disease, because 
up to nine in ten of those with celiac disease in Denmark are 
expected to be undiagnosed, and thus they are not registered.21
With regard to evaluation of the duodenal biopsies, the cat-
egorization according to the Marsh classification system relied 
on the pathologists’ reports. Incorrect classifications may 
have occurred as a result of poor-quality biopsies or biopsies 
that failed to encompass the diseased areas of the duodenum, 
or some of the pathologists may have been inexperienced, 
leading to incorrect descriptions being recorded.22–24 These 
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issues were not taken into account in this study unless they 
were specifically mentioned in the pathology reports. Some 
studies have reported a considerable degree of interobserver 
variation in SNOMED coding,24–26 although other studies 
have reported that there is a good level of agreement between 
duodenal biopsies, SNOMED codes, and clinical diagnoses.17
Overall, our results may have been affected by uncertainties 
regarding the diagnostic items, the lack of information on symp-
toms, and the lack of other potentially relevant information. 
Incomplete information on biopsies or antibodies may have led 
to an underestimation of the number of correct registrations. 
However, our use of diagnostic criteria that are less strict than 
those recommended in the diagnostic guidelines may have led 
to an overestimation of the number of correct registrations.
The validity of the registrations seemed to have increased 
over time. This may be attributable to an increase in the 
number of correct registrations by clinicians due to improved 
diagnoses and/or a decrease in the number of missing test 
results over time. PPV was slightly increased when the 
diagnostic criteria associated with the registrations were 
made more restrictive by stipulating that there had to be two 
or more registrations. However, this occurred at the cost of 
missing multiple definite diagnoses of celiac disease. The 
considerable drop in the proportion of children diagnosed 
on the basis of biopsies after the implementation of the new 
diagnostic guidelines in 2013 confirms that validation should 
involve more than just pathology reports on biopsies.
The prevalence of celiac disease is increasing,27,28 and 
there is substantial variation between countries.21,29,30 This 
indicates that there are modifiable environmental factors 
that influence the development of the disease. Epidemiologic 
studies of the etiology of celiac disease are urgently needed if 
we are to identify the potentially preventable factors that are 
responsible for the increase in prevalence.31 Studies based on 
data obtained from national register-based studies are useful, 
as they ensure that sufficiently large study populations can be 
studied and that the study populations are not self-selected. 
Databases based on accurate diagnoses are needed in order 
to use the data to address the key questions.
Our findings suggest that the Danish National Patient 
Register could be a valuable source to identify diagnosed 
cases of celiac disease. However, the validity of the celiac 
disease registrations is suboptimal, and validation of the 
data is warranted before they are used for research purposes.
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Supplementary materials
Table S1 Celiac disease-related SNOMED codes
Topographic codes Morphologic codes Diagnostic codes
T63910, T63911, T63930, T63950, T63951, T64000, T64020, 
T64040, T64300, T64320, T64910, T63950, T65100, T65110, 
T65930, T65935
M42100, M43000, M43005, M43009, M43900, 
M47195, M58000, M58015, M58018, M71000, 
M72000, M72115
S62180
Note: We applied for Patobank records that contained relevant topographic and morphologic codes or diagnostic codes.
Abbreviation: SNOMED, Systematized Nomenclature of Medicine.
Table S2 Classification of duodenal biopsy procedures recorded in the Patobank, based on microscopic histological descriptions, 
conclusions, and selected SNOMED codes
SNOMED code Classification of biopsies
Compatible with 
Marsh 2–3 (n=1,233)
Compatible with 
Marsh 1 (n=220)
Unclassifiable 
(n=44)
Compatible with 
Marsh 0 (n=1,078)
Total (n=2575)
S62180 (celiac disease) 697 (29) 48 (20) 2 (0) 3 (0) 750 (49)
M58018 (crypt hypertrophic 
villous atrophy)
824 (42) 3 (0) 9 (4) 7 (1) 843 (47)
M47195 (intraepithelial 
lymphocytosis)
261 (11) 124 (66) 4 (1) 23 (16) 412 (16)
M4 (inflammation and fibrosis) 717 (30) 217 (94) 14 (10) 715 (590) 1673 (724)
M5 (degeneration, necrosis, 
deposition, atrophy)
1027 (52) 11 (2) 19 (6) 57 (43) 1114 (103)
M4 or M5 or S62180 1232 (63) 219 (94) 34 (11) 736 (603) 2221 (771)
Note: Data shown as number (number not registered in the Danish National Patient Register).
Abbreviation: SNOMED, Systematized Nomenclature of Medicine.
Table S3 Records of celiac disease-specific antibodies by the type of hospital department that provided the recordsa
Charateristics Medical records accessed Medical 
records not 
accessed
Total
Pediatric 
departments
Departments of 
internal medicine
Other 
departments
Departmentsc 17 22 7 26 72
Childrenc;d 1,927; 104 (25–276) 178; 4 (1–42) 30; 2 (1–17) 112; 2 (1–28) 2,247; 7 (1–276)
Antibody registrations 10,021 1,111 72 48b 11,252
Antibody registrations per childd 5 (0–30) 6 (0–27) 2 (0–7) (0–7)b 4 (0–30)
≥1 positive antibody testse 1,346 (70) 143 (80) 12 (40) 9b 1,510 (67)
tTG2 at ≥10¥ ULN or 
positive EMAe
998 (52) 109 (61) 7 (23) 6b 1,120 (50)
Biopsy compatible with 
Marsh 2–3e
955 (50) 121 (68) 8 (27) 43 (38) 1,127 (50)
Notes: a2,247 of the children were registered as having celiac disease in the Danish National Patient Register; bresults that were based solely on antibody-test results from 
the SSI laboratory or the GastroLab (numbers expected to be higher when medical records accessed); Data shown as cnumber; dmedian (range) or enumber (%).
Abbreviations: ULN, upper limit of normal; EMA, endomysial antibody; HLA, human leukocyte antigen; SSI, Statens Serum Institut; tTG2, anti-tissue transglutaminase 2.
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